PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3
Completed
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT00904670
- Locations
- 🇺🇸
UC Irvine Child Development Center, Irvine, California, United States
🇺🇸Center for Psychiatry and Behavioral Medicine, Incorporated, Las Vegas, Nevada, United States
A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00902187
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
CP-690,550 and Midazolam Drug-Drug Interaction Study
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: midazolam; CP-690,550 + midazolamDrug: CP-690,550 + midazolam; midazolam
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2009-08-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT00902460
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Study Of Early Markers Of Choroidal Neovascularization
Terminated
- Conditions
- Choroidal Neovascularization (CNV)Age-related Macular Degeneration (AMD)Early Markers
- Interventions
- Other: no drug
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2010-11-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT00902785
- Locations
- 🇬🇧
Pfizer Investigational Site, Belfast, United Kingdom
A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00902681
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Study Evaluating Predictors of Response in Patients With Ankylosing Spondylitis
Completed
- Conditions
- Ankylosing Spondylitis
- Interventions
- Other: Treatment switching
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2012-06-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 132
- Registration Number
- NCT00900796
- Locations
- 🇪🇸
Pfizer Investigational Site, Madrid, Spain
Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease
Phase 2
Terminated
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 526
- Registration Number
- NCT00895895
- Locations
- 🇿🇦
Pfizer Investigational Site, Cape Town, South Africa
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
Phase 4
Completed
- Conditions
- Graft RejectionKidney TransplantRenal TransplantRenal Allograft Recipients
- Interventions
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 254
- Registration Number
- NCT00895583
- Locations
- 🇪🇸
Pfizer Investigational Site, Valencia, Spain
Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects
Phase 1
Completed
- Conditions
- Falciparum Malaria
- Interventions
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2010-06-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT00894374
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
Study Evaluating Pharmacovigilance Of Refacto AF
Completed
- Conditions
- Hemophilia A
- Interventions
- Drug: ReFacto AF (Moroctocog alfa)
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 101
- Registration Number
- NCT00895037
- Locations
- 🇦🇹
LKH - Univ. Klinikum Graz,Abt. fur Hamatologie, Graz, Austria
🇦🇹Allgemeines Krankenhaus Linz, Kinderklinik, Linz, Austria
🇦🇹Universitaetsklinik fuer Innere Medizin 1, Wien, Austria